

UNITED STATES NUCLEAR REGULATORY COMMISSION

WASHINGTON, D.C. 20555-0001

October 31, 2014

Gregory Piefer, Ph.D.
Chief Executive Officer
SHINE Medical Technologies, Inc.
2555 Industrial Drive
Monona, WI 53713

Dear Dr. Piefer,

The U.S. Nuclear Regulatory Commission (NRC) is pleased that you will participate in a public Commission meeting on research and test reactors, and medical isotopes, December 16, 2014 at 9:00 a.m. The meeting will be held in the Commissioners' Conference Room on the first floor of the NRC's Headquarters building at One White Flint North, Rockville, Maryland. The Commission is interested in hearing your views on licensing activities for SHINE's medical isotope facility and current licensing status of SHINE's domestic production of Molybdenum-99 technology. I am enclosing a copy of the meeting agenda for your information (enclosure 1).

To assist the Commission in preparing for the meeting, please e-mail any written material, including slides, to Mr. Glenn Ellmers (<u>Glenn.Ellmers@nrc.gov</u>) and Ms. Pamela Shea (<u>Pamela.Shea@nrc.gov</u>) in the Office of the Secretary, by <u>December 9, 2014</u>, so that it can be distributed to the Commission for review in advance of the meeting. Enclosed are guidelines for slides, if you choose to use them (enclosure 2). PowerPoint is the preferred format, but other electronic presentation formats may be used. This Commission meeting will be webcast live at the Web address: <u>www.nrc.gov</u>, and materials provided for the meeting will be posted on the NRC public website prior to the meeting: http://www.nrc.gov/reading-rm/doc-collections/commission/tr/. If you have any questions, please contact Mr. Ellmers at 301-415-0442.

Your presentation at the Commission meeting should be based on the assumption that Commissioners are familiar with the content of your written material. Please plan your oral presentation for 8 minutes, discussing the important points on which you wish to focus the Commission's attention. Please avoid the use of acronyms. If you do use acronyms, please explain them during your presentation.

The NRC Headquarters building is located opposite the White Flint Metro Station on Rockville Pike and Marinelli Drive, Rockville, Maryland. The White Flint Metro Station is on the Red Line of the Washington area subway system. Reserved visitor parking for Commission guests is available. If you wish to use reserved parking, please notify Ms. Bavol in advance. If reserved parking has been arranged, please check-in with the security staff at the entrance to the NRC campus on Marinelli Drive when you arrive. A Security Guard will call for an escort.

Please note that visitors will be screened through metal detectors, will have their packages x-

rayed, and will be required to present a picture identification card prior to signing in at the registration desk.

Sincerely,

Annette Vietti-Cook

Secretary of the Commission

Enclosures:

- Agenda
 Guidelines for Slides

Final: 9/18/14

SCHEDULING NOTE

Title:

UPDATE ON RESEARCH AND TEST REACTORS INITIATIVES

(Public Meeting)

Purpose:

To provide an overview of the research and test reactors (RTR)

licensing program, including the status of license renewals and

domestic production of medical isotopes.

Scheduled:

December 16, 2014

9:00 am

Duration:

Approx. 3 hours

Location:

Commissioners' Conference Room, 1st fl OWFN

Participants:

Presentation

External Panel

32 mins.*

8 mins.*

Thomas Newton, Ph. D., Chair, The National Organization of Test,

Research and Training Reactors, Inc. (TRTR) and Director of

Reactor Operations and Associate Director for Reactor Engineering,

Massachusetts Institute of Technology

Topic: Challenges facing the RTRs

Gregory Piefer, Ph.D., Chief Executive Officer, SHINE Medical

8 mins.*

Technologies, Inc.

<u>Topic:</u> Licensing activities for SHINE's medical isotope facility and current licensing status of SHINE's domestic production of

Molybdenum-99 technology

Paul J. O'Connor, Ph.D., Director, Dow Chemical TRIGA Research Reactor 8 mins.*

<u>Topic:</u> Successes and challenges associated with a completed RTR license renewal review associated with the Dow Chemical

research reactor

Ralph Butler, Director, Missouri University Research Reactor (MURR)

Tonic: Status and challenges associated with an RTR license

<u>Topic:</u> Status and challenges associated with an RTR license renewal review for MURR, which is currently under staff review

8 mins.*

Commission Q & A

50 mins.

Break

5 mins.

NRC Staff Panel 35 mins.*

Mark Satorius, Executive Director for Operations

Lawrence Kokajko, Director, Division of Policy and Rulemaking (DPR),
Office of Nuclear Reactor Regulation (NRR)
Topic: Introduction and NRC organization structure for RTR regulation

Alexander Adams, Jr., Branch Chief, RTR Licensing Branch, NRR/DPR

<u>Topic:</u> Current status of staff's efforts associated with RTR license renewal reviews, high-enriched to low-enriched uranium RTR conversions, and the RTR Streamlining Rule

Steve Lynch, Project Manager, RTR Licensing Branch, NRR/DPR

<u>Topic</u>: Current status of NRR staff efforts related to medical isotope production facility licensing actions

Commission Q & A

50 mins.

Discussion - Wrap-Up

5 mins.

Documents:

Staff background materials due to SECY: December 2, 2014.

Slides due to SECY: December 9, 2014.

^{*}For presentation only and does not include time for Commission Q & As

- Use company/organization logo, and light background.
- be easily readable. Slides should contain substantive information, including text, photos, and graphics and
- Explain/spell out acronyms or include a separate slide with a list of acronyms
- Number pages
- Margins should be 1 inch.

PRESENTATION TITLE (Arial Black 40)

Name and Title of Presenter **Date of Briefing** (Arial Black 32)

Slide Title – Arial Black 36

Text (Arial Black 32) on white.